This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Effective Will Vaccines be Against New Coronavirus Strain?
by Indrajit Bandyopadhyay
Pfizer (PFE) and Moderna (MRNA), the companies whose coronavirus vaccines have been approved for emergency use, are evaluating their vaccines against the fast-spreading new strain of coronavirus found in the United Kingdom.
Forget Sector Rotation: Tech ETFs to Rule in Christmas Week
by Sanghamitra Saha
News of new virus strain in the UK will likely keep the market subdued this week and brighten the appeal for tech ETFs.
Pfizer/BioNTech COVID-19 Vaccine Gets Authorization in Europe
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate is the first COVID-19 vaccine to be granted conditional authorization in Europe.
5 Small-Cap ETFs Set to Explode on COVID-19 Vaccines
by Sweta Killa
As the economy seems on track for strong growth, a small-cap rally is expected to strengthen in the New Year.
Christmas Week Begins With Pre-market Sell-off
by Zacks Equity Research
Christmas Week Begins With Pre-market Sell-off
Pre-Markets Down to Start Christmas Week
by Mark Vickery
Though already off the lows we saw a couple hours before today's opening bell, the Dow is down 400 points, the S&P 500 -55 and the Nasdaq -140.
Moderna (MRNA) Gets FDA Emergency Use Nod for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) gets emergency use authorization for coronavirus vaccine, mRNA-1273, for use in adults in the United States.
4 Restaurant Stocks to Watch as Vaccine Rollout Begins
by Zacks Equity Research
Vaccine rollout should allow dine-in to resume in restaurants with online delivery expected to sustain, making it prudent to keep an eye on names like Brinker International (EAT) and McDonald's (MCD)
Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use to Moderna's (MRNA) coronavirus vaccine candidate.
J&J (JNJ) Coronavirus Vaccine Candidate Study Fully Enrolled
by Zacks Equity Research
Johnson & Johnson (JNJ) phase III study on its experimental COVID-19 single-dose vaccine candidate is now fully enrolled.
FDA Approves Second COVID-19 Vaccine
by Zacks Equity Research
FDA Approves Second COVID-19 Vaccine.
Markets, Covid Deaths at New All-Time Highs
by Mark Vickery
The coronavirus posted a new one-day high in both cases -- 241,620 -- and fatalities -- 3,438 -- on Thursday.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Markets Set New Record Closes; FedEx Beats on Q2 (revised)
by Mark Vickery
It's the S&P 500's 31st all-time closing high this year, and Nasdaq is on pace for its strongest full-year performance since 2009.
Markets Set New Record Closes; FedEx Beats on Q2
by Mark Vickery
It's the S&P 500's 31st all-time closing high this year, and Nasdaq is on pace for its strongest full-year performance since 2009.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
10 Best Performing Leveraged ETFs of 2020
by Sweta Killa
This year has witnessed historic twists and turns with the largest bull market turning into a bear market in March on the coronavirus outbreak, and then marking the fastest-ever recovery.
5 Beaten-Down Energy Stocks to Buy for a Turnaround in 2021
by Nilanjan Choudhury
With energy set for a strong 2021 on vaccine-led demand boost, 5 underperformers of this year - DCP Midstream (DCP), Sinopec (SNP), Vermilion Energy (VET), NOW (DNOW) and Enerplus (ERF) - are likely to rebound.
These Stocks Could Be Your Secret Santa This Christmas
by Sweta Killa
Looking for a surprise this Christmas? Bet on these stocks - BJs Wholesale (BJ), Gogo (GOGO), TRI Pointe (TPH), Penske Automotive (PAG), and Santander Consumer (SC) - for big returns.
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.
Moderna (MRNA) Vaccine May Get Emergency Approval This Week
by Zacks Equity Research
An advisory committee meeting is scheduled on Dec 17 to discuss emergency use authorization for Moderna's (MRNA) COVID-19 vaccine candidate, mRNA-1273.
6 Secret Santa ETFs to Add Cheer to Your Portfolio
by Sweta Killa
While most of the ETFs have been surging over the past month, there are some hidden gems or Secret Santa as we call them that could surprise investors with big returns this Christmas based on the current trends.
Stock Market News for Dec 16, 2020
by Zacks Equity Research
Wall Street closed sharply higher on Tuesday buoyed by investors' renewed hopes for a fresh round of coronavirus-aid package by this week end.
5 Small-Cap Sector ETFs Beating the Russell 2000
by Sweta Killa
We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.